CSI Market
Sign In | Register

Immune Design (IMDZ) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access IMDZ Annual Cash Flow →
The cash flow figures below highlight longer-term patterns in how Immune Design manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2018)
12 Months 		(Sep 30 2018) (Jun 30 2018) (Mar 31 2018) (Dec 31 2017)
Operating Activities
Income-54.76
Depreciation & amortization0.35
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.59
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation7.28
Income (Loss) from Equity Method Investments0.00
Increase (Decrease) in Restricted Cash for Operating Activities0.00
Increase Decreasein Estimated Litigation Liability-6.00
Increase Decrease In Deferred Revenue and Other Current Liabilities0.01
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable1.29
Increase (Decrease) in Accounts Payable-0.86
Increase (Decrease) in Accrued Liabilities1.18
Increase (Decrease) in Security Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.18
Other Working Capital0.01
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.56
Discontinued operations0.00
Net Cash flow from Operating Activities-51.67
Investing Activities
Capital Expenditures-0.39
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities86.00
Payments to Acquire Available-for-sale Securities-34.69
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities50.93
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.23
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Increase Decrease Deferred Offering Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.23
Effect of exchange rate on cash flow-0.51
Discontinued operations0.00
Free Cash Flow-52.06
Total Cash Flow-0.51
4 historic quarters locked

Sign in to unlock the full Immune Design cash flow history.

Sign In Create Free Account

About IMDZ Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.